Form 4: Apellis General Counsel Reports Future Stock Sale
Insider Transaction Report
Apellis Pharmaceuticals General Counsel David O. Watson reported a planned sale of 20,000 shares of common stock for approximately $26.17 per share, effective September 10, 2025.
Summary
- David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (APLS), filed a Form 4 reporting a transaction.
- The filing indicates a planned sale of 20,000 shares of Apellis Common Stock.
- The transaction is scheduled to occur on September 10, 2025.
- The shares were sold at a weighted average price of $26.17, with individual transactions ranging from $26.15 to $26.20.
- This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-scheduled.
- Following this planned transaction, Mr. Watson will beneficially own 183,866 shares of Common Stock.
- Beneficial ownership includes 123,730 shares held directly, 50,136 shares held indirectly by The David O. Watson Irrevocable Trust of 2023, and 10,000 shares held indirectly in a custodial account for minor children.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transaction is a pre-scheduled sale under a 10b5-1 plan, which typically indicates a planned liquidity event rather than a discretionary sale based on new, non-public information. This mitigates any potential negative interpretation often associated with insider selling.
Future Outlook
The filing reports a pre-scheduled future transaction under a Rule 10b5-1 plan, indicating a planned sale of shares by the General Counsel on September 10, 2025.
Industry Context
This is a routine insider transaction filing for a biotechnology company. Such filings are common and provide transparency into executive stock ownership changes, particularly when executed under a pre-arranged 10b5-1 plan.
Stakeholder Impact
- Shareholders: Provides transparency regarding a planned reduction in direct ownership by a key executive, though mitigated by the 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 09/10/2025 | Date of planned transaction (sale of common stock) |
| 09/12/2025 | Date the Form 4 was signed by the reporting person |
Keywords
Apellis Pharmaceuticals, APLS, Insider Transaction, Form 4, Stock Sale, David O. Watson, General Counsel, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.